Home About us Contact
|
Home About us Contact | ||
|
|
||
Therapeutic Indications (therapeutic + indication)
Selected AbstractsPurine Metabolism in Heart Failure: Oxidant Biology and Therapeutic IndicationsCONGESTIVE HEART FAILURE, Issue 5 2008John Anthony Bauer PhD No abstract is available for this article. [source] Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responsesIMMUNOLOGY, Issue 2 2004Pallavur V. Sivakumar Summary Cytokines and their receptors represent key targets for therapeutic intervention. Ligands are being used to supplement cell numbers that become depleted as a result of disease (organ failure, infection) or subsequent disease treatments (i.e. chemotherapy). Conversely, the inhibition of target cell binding by cytokines is an established strategy for abrogating pathologic cellular activities common to many immunological diseases. Considerable effort in biomedical research is being focused on the cytokine families that play a dominant role in regulating immunity and then prioritizing each member for its therapeutic potential. Currently, the interleukin-2 (IL-2) family of cytokines is widely recognized for its central involvement in controlling lymphocyte function and is the most explored for medical utility. Collectively, these proteins (or their antagonists) are either marketed drugs or have received advanced testing for an impressive array of indications including cancer, infectious disease, transplantation, inflammation and allergic asthma. Here we review the current understanding of IL-21, the most recent member of this cytokine family to be discovered. As will be discussed, IL-21 shares many of the same attributes as its relatives in that it has broad immunoregulatory activity and can modulate both humoral and cell-mediated responses. Its ability to stimulate durable anti-tumour responses in mice defines one therapeutic indication that merits clinical development. [source] Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride,JOURNAL OF PHARMACEUTICAL SCIENCES, Issue 7 2005R.K. Verbeeck Abstract Literature data on the properties of chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride related to the Biopharmaceutics Classification System (BCS) are reviewed. The available information indicates that these chloroquine salts can be classified as highly soluble and highly permeable, i.e., BCS class I. The qualitative composition of immediate release (IR) tablets containing these Active Pharmaceutical Ingredients (APIs) with a Marketing Authorization (MA) in Belgium (BE), Germany (DE), Finland (FI), and The Netherlands (NL) is provided. In view of these MA's and the critical therapeutic indication of chloroquine, it is assumed that the registration authorities had evidence that these formulations are bioequivalent to the innovator. It is concluded that IR tablets formulated with these excipients are candidates for a biowaiver. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 94:1389,1395, 2005 [source] Therapeutic intent of proton pump inhibitor prescription among elderly nonsteroidal anti-inflammatory drug usersALIMENTARY PHARMACOLOGY & THERAPEUTICS, Issue 6 2009A. M. DRIES Summary Background, Prescription of proton pump inhibitors (PPIs) has increased dramatically. Aim, To assess therapeutic intent of PPI prescription among elderly veterans prescribed nonsteroidal anti-inflammatory drugs. Methods, Medical-record abstraction identified therapeutic intent of PPI prescription. An ,appropriate therapeutic intent' was defined as symptomatic gastro-oesophageal reflux disease or endoscopic oesophagitis, Zollinger,Ellison disease, dyspepsia, upper gastrointestinal event, Helicobacter pylori infection or nonsteroidal anti-inflammatory drug gastroprotection. Logistic regression predicted the outcome while adjusting for clinical characteristics. Results, Of 1491 patients [mean 73 years (s.d. 5.6), 73% white and 99.8% men], among those charts which did document a therapeutic indication, 88.8% were appropriate. Prior gastroscopy was predictive of an appropriate therapeutic intent (OR 2.7; 95% CI: 1.9,3.7). Prescription to patients who used VA pharmacy services only, to in-patients, or by a cardiologist or an otolaryngologist were less likely to be appropriate. Gastroprotection was poorly recognized as an indication for PPI prescription, except by rheumatologists (OR 46.7; 95% CI: 15.9,136.9), or among highly co-morbid patients (OR 1.8; 95% CI: 1.1,2.9). Among in-patients, 45% of PPI prescriptions were initiated for unknown or inappropriate reasons. Conclusions, Type of provider predicts appropriate PPI use. In-patient prescription is associated with poor recognition of necessary gastroprotection and unknown therapeutic intent. [source] Alternative therapy in pruritusDERMATOLOGIC THERAPY, Issue 2 2003Larry E. Millikan ABSTRACT: Because of its multitude of origins, the symptom complex of pruritus has a plethora of purported remedies and few therapeutic indications. Very few topical and systemic FDA approved medications have the indication of pruritus. Specific therapy still awaits a better definition of the exact physiologic events in chronic pruritus. Hence most medications actually focus on the central nervous system,the peripheral receptors,and the lack of specific physiologic targets has inhibited pharmacologic development. The resulting gap has opened the door to a variety of alternative therapies. [source] Maximum Residue Limits of Veterinary Medicinal Products and Their Regulation in European Community LawEUROPEAN LAW JOURNAL, Issue 2 2003Robert Ancuceanu This paper proposes a legal analysis of a legal and empirical tool (maximum residue limits (MRLs)) designed to protect the consumers of animal foodstuffs, as it is regulated in European Community law. After introducing the concept of MRLs in its legal context, MRLs are defined and the need for harmonisation in this field is explained. Then the main rules governing the establishment of MRLs at a Europe-wide level are expounded, an important place being devoted to some problems occurred in the cases decided by the European Court of Justice: is it possible to establish an MRL only for certain therapeutic indications? What about the intention of placing on the market in the establishment of an MRL? Is the procedure for the establishment of MRLs a tight or lax one? The answer to some of these questions involves more general aspects of European Community law. [source] What is the impact of PRIME on real-life diabetic nephropathy?INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, Issue 3 2004L. M. Ruilope Summary Type 2 diabetes is increasing globally and is a major cause of conditions such as cardiovascular disease, retinopathy and nephropathy. The Diabetes Control and Complications Trial and the UK Prospective Diabetes Study demonstrated that the progression of renal disease could be slowed by tight glycaemic control and treating any associated hypertension with angiotensin-converting enzyme inhibition. Recent clinical trials have supported the use of angiotensin II receptor antagonists in the treatment of diabetic nephropathy, resulting in the approval of new therapeutic indications in the United States and Europe. The objective of this review is to demonstrate how results from the Program for Irbesartan Mortality and morbidity Evaluation studies apply to clinical practice, and to show how the benefits of irbesartan therapy can be realised at any stage of renal disease in patients with diabetes. [source] Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone,,JOURNAL OF PHARMACEUTICAL SCIENCES, Issue 1 2007M. Vogt Abstract Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing prednisolone are reviewed. Data on its solubility, oral absorption, and permeability are not totally conclusive, but strongly suggest a BCS Class 1 classification. Prednisolone's therapeutic indications and therapeutic index, pharmacokinetics, and the possibility of excipient interactions were also taken into consideration. Available evidence indicates that a biowaiver for IR solid oral dosage forms formulated with the excipients tabulated in this article would be unlikely to expose patients to undue risks. © 2006 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 96:27,37, 2007 [source] Concise semiquantitative histological scoring system for immunoglobulin A nephropathyNEPHROLOGY, Issue 6 2009LEI JIANG SUMMARY: Aim: Immunoglobulin A nephropathy (IgAN) is a common and progressive glomerulonephritis. Histological lesions of IgAN are variable and considered as a risk factor for renal outcome. Establishing a relatively concise histological semiquantitative scoring system would be valuable in clinical practice. Methods: Renal biopsy sections of 293 patients with primary IgAN from two centres in China were reviewed. A histological scoring system was established based on multivariate survival analysis of semiquantitative histological indices, using end-stage renal disease (ESRD) as the end-point event. Results: Four indices , extracapillary glomerular activity index (exGAI), mesangial proliferation index (MsI), glomerular chronicity index (GCI) and tubulointerstitial chronicity index (TCI) , independently correlated with ESRD (relative risk (RR) = 1.16, 2.27, 1.29 and 1.80, respectively). The four indices and the sum of their scores (Total I) constituted the scoring system. Patients with exGAI of 4 or more, GCI of 4 or more, MsI of 2 or more and TCI of 2 or more were considered as having a higher risk for progression (P < 0.05). A score of 4 or more on the exGAI index could identify the patients who should be treated with immunosuppressive drugs, which showed a lower incidence of ESRD than that without (24.3% vs 52.4%, P = 0.031). Conclusion: It suggested that the present concise scoring system could serve as prognostic and therapeutic indications. [source] New therapeutic indications for Cys-LT1 antagonists: atopic dermatitis and urticariaCLINICAL & EXPERIMENTAL ALLERGY REVIEWS, Issue 2 2001P S Friedmann First page of article [source] | ||||||||||